ARIAD to Webcast Conference Call on Second Quarter 2009 Financial Results and Clinical Data Released Today.CAMBRIDGE, Mass. -- ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARIA) will hold a live webcast of its quarterly conference call at 4:15 p.m. (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) on Thursday, July 30, 2009. In addition to discussing the Company's financial results for the six months ended June 30, 2009 and progress toward achievement of 2009 corporate objectives, senior management will also discuss the preliminary clinical results on AP24534 released earlier this morning. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. The Company will announce the highlights of the financial results in a press release to be issued immediately following the market close on July 30, 2009 and prior to the conference call. The live webcast can be accessed by visiting the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website at http://www.ariad.com/investor. The call can be accessed by dialing 800-561-2813 (domestic) or 617-614-3529 (international) five minutes prior to the start time and providing the passcode 59246348. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas Sarcomas Definition A sarcoma is a bone tumor that contains cancer (malignant) cells. A benign bone tumor is an abnormal growth of noncancerous cells. Description A primary bone tumor originates in or near a bone. and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase kinase /ki·nase/ (ki´nas) 1. a subclass of the transferases, comprising the enzymes that catalyze the transfer of a high-energy group from a donor (usually ATP) to an acceptor. 2. inhibitor in Phase 1 clinical development in patients with hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion